PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Fumiko Kiyonaga

Astellas Pharma (Japan)

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs1 Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 6, 2026 · JOURNAL ARTICLE

Real-World Longitudinal Treatment Outcomes for Patients with Metastatic Castration-Sensitive Prostate Cancer in Japan

Advances in Therapy

Large real-world retrospective cohort with prospectively collected data, clear PSA endpoints, and adjusted analysis demonstrating consistent superiority of ARSI-based regimens over ADT monotherapy in mCSPC, though limited by surrogate endpoints and lack of hard clinical outcomes.

Strong EvidenceAtsushi Saito Prostate Cancer Treatment and Research Satoshi Uno

Reported

Cumulative PSA-90 at 3 months (AD…63.2%

Cumulative PSA-90 at 3 months (AD…69.3%

Cumulative PSA-90 at 3 months (AD…91.8%

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support